FDA Clearance Supports Start of Phase 2 Trial of TNX-102 SL for Agitation in Alzheimer’s Patients
News
The U.S. Food and Drug Administration (FDA) approved Tonix Pharmaceuticals’ investigational new drug (IND) application to support the start of a Phase 2 trial of TNX-102 SL in Alzheimer’s ... Read more